Vol. 19/No. 2 | OncologyLive

Combos May Extend Reach of CDK4/6 Inhibitors in Breast Cancer

January 29, 2018

Oncology drug developers have been able to leverage knowledge about a cause of proliferation— dysregulated activity of the cyclin-dependent kinases (CDKs)—to create a new class of therapy that has rapidly been integrated into the breast cancer treatment paradigm.

Effective Management of CINV Improves Response to Treatment

January 26, 2018

The goal of selecting optimal antiemetic therapy continues to be a moving target with the emergence of newer agents and patient-related risk factors, as well as the rapid evolution of guidelines for the management of chemotherapy-induced nausea and vomiting.

Microbiome Emerges as a Hot Topic in Cancer Research

January 19, 2018

Researchers have found relationships between the oral microbiome and esophageal cancer; between the vaginal and uterine microbiomes and endometrial cancer; and between the gut microbiome and the efficacy of checkpoint inhibitors.

Proving "Noninferiority" May Become Another Challenge in Oncology Studies

January 17, 2018

Fewer than 4% of patients with cancer in the United States participate in clinical trials, the elderly and individuals with clinically relevant comorbidities are strikingly underrepresented in the research portfolio.